Introduction: Immune escape frequently occurs and restricts the durability of the antitumor immune response to radiotherapy. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important immune checkpoint molecules that could cause tumor cells to escape the host immune response. The aim of the study was to explore the role of PD-L1 in radioresistance and the antitumor effect of combined radiotherapy and anti-PD-L1 therapy in NSCLC.
Introduction
Despite substantial improvements in molecular targeted therapy, lung cancer remains the leading cause of cancer-related mortality worldwide, with a dismal 5-year survival rate. 1 Radiotherapy is the most import nonsurgical treatment in the multidisciplinary management of patients with NSCLC. 2, 3 In addition to DNA damage and modulation of signal transduction, specifically, radiation-induced antitumor processes also include alteration of the tumor microenvironment. [4] [5] [6] Radiation can regulate host immune response to the tumor site by triggering recruitment and activation of antigen-presenting cells and priming of tumor antigenspecific T-cell responses by releasing several damageassociated molecular patterns. [7] [8] [9] [10] However, immune escape frequently develops with tumor relapse, 11, 12 thus restricting the durability of the antitumor immune response to radiotherapy.
Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) have been characterized as important immune checkpoint molecules that could cause tumor cells to escape the host immune response through inhibition of effector T-cell function and induction of T-cell exhaustion. 13 In addition to inflammatory cytokines, among which interferon gamma (IFN-g) is the most potent, PD-L1 expression can also be regulated in an oncogenic habitat, such as activation of the EGFR, phosphoinositide 3-kinase (PI3K)/AKT, and MEK/ERK pathways. [14] [15] [16] [17] [18] Intriguingly, a recent study by Dovedi et al. has demonstrated that after delivery of radiotherapy, tumor cell PD-L1 expression is up-regulated by IFN-g produced by CD8-positive T cells. 19 Furthermore, radiation can induce a local inflammatory response and simultaneously induce PD-L1 expression in the tumor microenvironment, which attenuates the sensitivity of antitumor immune response. 20 Thus, if PD-1/PD-L1-induced immune escape can be overcome, radiotherapy may have the potential to generate durable responses against tumor cells.
Currently, immunotherapy targeting the PD-1/PD-L1 axis has substantially shifted the strategies for treatment of patients with advanced NSCLC. 21 To date, PD-1 monoclonal antibodies, including pembrolizumab and nivolumab, have been approved as standard second-line treatment for NSCLC after failure to respond to chemotherapy. [22] [23] [24] In spite of this, broadening the population of patients benefiting from anti-PD-1/PD-L1 antibodies is still an unmet need in clinical practice because few patients with NSCLC respond to anti-PD-1/PD-L1 antibodies. Interestingly, a recent phase I study suggests that nivolumab plus platinum-based doublet chemotherapy may synergistically enhance antitumor efficacy in patients with advanced NSCLC as first-line therapy. 25 Furthermore, in models of melanoma, colorectal cancer, and triple-negative breast cancer, the antitumor efficacy of radiotherapy can be improved when delivered in combination with PD-1 antibody, which also provides a rationale for a combined treatment strategy. 20 Here, we demonstrate that conventionally fractionated radiotherapy may lead to PD-L1 overexpression on tumor cells through activation of PI3K/AKT and signal transducer and activator of transcription 3 (STAT3) pathways in NSCLC cell lines. Moreover, PD-L1 may also stimulate cell migration and facilitate the epithelialmesenchymal transition (EMT) process to induce radioresistance. Importantly, combined radiotherapy and anti-PD-L1 antibody synergistically enhances the antitumor immunity by eradicating the local accumulation of tumor-infiltrating regulatory T cells (iTregs) and myeloid-derived suppressor cells (MDSCs) and stimulating CD8-positive T-cell infiltration, which provides a rationale for the combination of radiotherapy and anti-PD-L1 antibody in NSCLC.
Materials and Methods

Patients and Tissue Collection
A total of 76 patients with recurrent NSCLC after surgical resection who received concurrent chemoradiotherapy from January 2009 to December 2013 were enrolled in the present study. The tumor tissues were fixed in 10% neutral-buffered formalin and stored as paraffin-embedded archival (FFPE) samples. PD-L1 immunohistochemistry (IHC) testing was performed on FFPE samples. All tissues were reviewed by experienced pathologists for confirmation of histological type and a tumor content higher than 30%. Tumor response was assessed every 8 weeks according to the Response Evaluation Criteria in Solid Tumor (RECIST, version 1.1). This study was approved by the Ethics Committee of Shanghai Pulmonary Hospital, Tongji University, and written informed consent was obtained from each participant before any study-related procedures.
Cell Culture PC9, H520, Lewis lung cancer (LLC), and A549 cells were obtained from the American Type Culture Collection (Manassas, VA). PC9/R and A549/DDP were obtained as previously described. 26 The cell line A549/X was induced by conventionally fractionated radiation in our laboratory as follows. A549 cells in the logarithmic growth phase received radiation by a medical linear accelerator. The radiation field was 10 Â 10 cm. The source skin distance (SSD) was 100 cm. Radiation was delivered in 2-Gy fractions once a day for a total of 25 fractions. After delivery in 25 fractions, we subcultured cells every 3 days with no more than 15 passages. We screened the A549 radioresistant cells and named them A549/X cell line.
All cells were cultured in Dulbecco's modified Eagle medium (Hyclon, Longan, UT) containing 10% fetal bovine serum (Life Technologies, Grand Island, NY) at 37 C with 5% CO 2 . All cell lines for research were cultured for fewer than 20 generations and routinely screened to confirm the absence of Mycoplasma contamination.
Western Blot Analysis
Cells were lysed by using radioimmunoprecipitation protein extraction reagent (Beyotime, Beijing, China) supplemented with phenylmethanesulfonyl fluoride (Roche, Pleasanton, CA). Approximately 25 mg of protein extracts was separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes (Sigma, St. Louis, MO), and incubated with specific antibodies. An enhanced chemiluminescence chromogenic substrate was used to visualize the bands. All of the rabbit monoclonal antibodies were purchased from Cell Signaling Technology (Danvers, MA), including PD-L1 (1:5000), tripartite motif-containing 21 (TRIM 21), nuclear factor kappa B (NF-kB), AKT phospho (Ps473) (1:2500), AKT (1:2500), STAT3 phospho (Ps705) (1:3000), STAT3 (1:3000), Ecadherin, N-cadherin, Snail, Vimentin, caspase-9, and caspase-8 (1:5000). Rabbit anti-glyceraldehyde-3-phosphate dehydrogenase antibody (1:2500) was detected simultaneously as a control. The experimental groups are representative of at least three independent experiments.
Flow Cytometry
Cells were harvested and centrifuged at 1000 g for 5 minutes at 4 C. Pellets were washed twice with ice-cold phosphate-buffered saline (PBS), and the apoptosis rate was determined by flow cytometry with a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) after staining with fluorescein-conjugated annexin V and propidium iodide (BD Biosciences) according to the manufacturer's instructions for the apoptosis staining with isotype control and PE mouse anti-human PD-L1 (BD Biosciences). The experimental groups are representative of at least three independent experiments.
Xenograft Study
We used 5-week-old female specific pathogen-free C57/BL6 mice. The animal studies were approved by our institutional animal care and use committee. LLCs were injected into the right outer thighs of the mice, and the murine PD-L1 antibody (BD Biosciences) was started 10 days after the tumor cell inoculation. The murine PD-L1 antibody was administered by intraperitoneal injection on 3 days during the first week at a dose of 250 mg.
Tumor sizes were assessed three times per week with a digital caliper. The tumor volumes were determined by measuring their length and width and calculating the volume as follows: V ¼ l Â w 2 /2, where V stands for volume, l stands for length, and w stands for width. After 4 or 12 days of treatment, the mice were killed and paraffin-embedded tissues were prepared for IHC staining. The experimental groups contained at least six mice per group and were representative of at least three independent experiments.
IHC
FFPE xenograft tumors, 4 mm thick, were dewaxed in xylene, hydrated in graded alcohols, and washed with PBS. After endogenous peroxidase activity had been blocked with a 3% H 2 O 2 aqueous solution for 10 minutes, the sections were incubated with primary antibodies overnight. After washing with PBS, they were then incubated with general-type immunoglobulin G-horseradish peroxidase polymer (Dako, Carpenteria, CA) for 10 minutes, followed by 3,3 0 -diaminobenzidine for about 2 to 5 minutes. The sections were restained with hematoxylin for 1 minute and then dehydrated in graded alcohols, cleared in xylene, and shielded with coverslips. Five different high-power (Â400 magnification) fields at the hotspot in a cancer area were observed in each slide in blinded fashion by three independent observers. Specimens were scored as IHC 0, 1, 2, or 3 if less than 1%, 1% to 5%, 5% to 10%, or more than 10% stained cells per area were PD-L1-positive, respectively, as previously defined by Herbst et al. 27 We used rabbit polyclonal antibodies to PD-L1 (1:100), NFkB (1:100), CD8 (1:100), CD4 (1:500), Fox3p (1:500), LyGr (1:1000), and CD11b (1:1000) as the primary antibodies (Novus Biologicals, Littleton, CO). The experimental groups are representative of at least three independent experiments.
Colony Formation Assay
According to the radiation dose, different numbers of cells were seeded in 60-mm plates. Cells received radiation at doses of 0, 2, 4, and 6 Gy (2 Gy per fraction per day for 3 consecutive days) and were then fixed with 4% formaldehyde and stained with crystal violet, after which colonies containing more than 50 cells were counted and normalized to their corresponding nonirradiated control. Colony formation experiments were performed 14 days after the radiation. The survival rate was calculated as the plating efficiency of the irradiated samples relative to that of the sham-irradiated sample. 28 For the cell lines A549 and A549/X, each radiation dose sample was duplicated three times. A multitarget click model of SigmaPlot 12.5 (Systat Software, Inc., San Jose, CA) was used to fit cell survival curves. The mean lethal dose and surviving fraction at 2 Gy were calculated. The experimental groups are representative of at least three independent experiments.
siRNA Transfection
Cells (2 Â 10 5 ) were seeded into each well of six-well plates, incubated overnight, and then transfected with 100 nmol/L of small-interfering (si)-PD-L1 and a negative control (NC) purchased from RiboBio (Guangzhou, China) that consisted of Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA). The target sequence for si-PD-L1-RNA was as follows: sense strand, 5
0 -CAUAGUAGCUACAGACAGA dTdT-3 0 , antisense strand, and 3
0 -dTdT GUAUCAUCGAUGUCUGUCU-5 0 . Forty-eight hours after transfection, the cells were harvested for flow cytometry or Western blot analysis.
IP and Detection
Cells were harvested with trypsin-etylenediaminetetraacetic acid and lysed with immunoprecipitation (IP) buffer containing 150 mM sodium fluoride, 1% NP-40, 10% glycerol, aprotinin (10 mg/mL), and leupeptin (10 mg/mL) for 30 minutes on ice. Lysates were centrifuged and supernatants were collected. Equal amounts of protein were incubated with total PD-L1 antibody (Cell Signaling Technology) overnight at 4 C. Protein G was added and samples were incubated at 4 C for 2 hours before pellets were rinsed twice with IP buffer, resuspended in 15 mL of Laemmli buffer, and boiled at 95 C for 5 minutes. The supernatant was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis, and Western blot was performed as already described.
Statistical Analysis
Quantitative data was presented as mean plus or minus the SD or standard error of the mean (SEM) of three separate assays. Student's t test was used to compare the mean values, and the c2 test and Fisher's exact test were used to compare categorical values. p Values less than 0.05 were considered statistically significant. Statistical analysis was performed with the SPSS software package, version 17.0 (SPSS, Inc., Chicago, IL).
Results
Expression of PD-L1 Was Associated with the Response to Radiotherapy in Patients with NSCLC
A total of 76 patients with recurrent NSCLC who received concurrent chemoradiotherapy were enrolled.
Their median age was 66 years (range 40-83). Briefly, 88.2% of the patients were male, 28.9% were neversmokers, and 53.9% had squamous cell carcinoma. The demographic and clinical characteristics of the enrolled patients are presented in Table 1 .
PD-L1 expression were evaluated in all 76 patients. Staining of the specimens from 32.9% of the patients (25 of 76) was scored as IHC 0, those from 31.6% (24 of 76) were scored as IHC 1, those from 27.6% (21 of 76) were scored as IHC 2, and those from 7.9% (six of 76) were scored as IHC 3. Notably, the expression of PD-L1 was associated with smoking status and T stage (see Table 1 ). However, in our study, most patients who received radiotherapy relapsed after surgery, and only a few of patients had T3 or T4 tumors. So, we compared T1 tumors with T2, T3, and T4 tumors by using a c2 test and found that patients with T2, T3, and T4 tumors had higher levels of PD-L1 expression. Therefore, the association between PD-L1 expression and T stage needs further validation in larger sample study.
All patients were available for response assessment after delivery of conventionally fractionated radiotherapy. Forty-four patients achieved a partial response, 23 had stable disease, and nine had progressive disease as their best response. Therefore, the overall objective response rate (ORR) was 57.9% and the disease control rate (DCR) was 88.2%. Interestingly, the ORR (88% versus 43.1% [p < 0.001]) and DCR (100% versus 86.2% [p ¼ 0.026]) were significantly higher in patients with negative PD-L1 expression (IHC 0) than in those with positive PD-L1 expression (IHC 1, 2, and 3) (see Table 1 ), suggesting that PD-L1 expression may be a biomarker to predict the response to radiotherapy in NSCLC.
Increased PD-L1 Expression in Cell Lines after Conventionally Fractionated Radiotherapy
To evaluate the response of the cell lines A549, A549/ X, A549/DDP, PC9, PC9/R, and H520 to radiation, a clone formation assay was conducted to detect the growth inhibition of these six cell lines after delivery of radiation (2 Gy of radiation) (Fig. 1A) ; the respective survival rates (mean ± SD) were 51.83% plus or minus 1.61%, 75.9% plus or minus 2.1%, 88.50 plus or minus 1.32%, 38.00 plus or minus 2%, 88.27 plus or minus 2.83%, and 51.73 plus or minus 1.55% (p < 0.05). We further evaluated the protein expression of PD-L1 in these six cell lines before radiation (Fig. 1B) . The data showed that membrane PD-L1 expression in human NSCLC cell lines was positively correlated with the survival rate and thus identified a positive correlation between PD-L1 expression and radioresistance in NSCLC cell lines.
The expression of PD-L1 after conventionally fractionated radiotherapy (0, 2, 4, and 6 Gy in 2-Gy fractions, once a day) were evaluated in these six cells lines (Fig. 1C) . PD-L1 expression was increased after conventionally fractionated radiotherapy at the dose of 6 Gy delivered in three fractions in the cell lines A549, PC9, and H520 but not in the radioresistant (A549/X), chemoresistant (A549/DDP), and EGFR tyrosine kinase inhibitor-resistant (PC9/R) cell lines (see Fig. 1C ). The expression of PD-L1 in the cell lines A549, PC9, and H520 was also increased after conventional radiation at the dose of 6 Gy in vitro by flow cytometry (Fig. 1D) . The proportions of PD-L1-positive tumor cells in the cell lines A549, PC9, and H520 were significantly increased after conventionally fractionated radiotherapy, increasing from 0.5% to 24.7%, 0.1% to 7.5%, and 0.1% to 11% after delivery of 0 and 6 Gy in the cell lines A549, PC9, and H520, respectively (p < 0.01) (see Fig. 1D ).
Down-regulating PD-L1 Could Alleviate Radiation Resistance by Promoting Apoptosis
To further investigate the role PD-L1 involving radioresistance, we induced the A549 radioresistance cell line (A549/X) as described earlier. To verify the relationship between PD-L1 and radioresistance, a monolayer wound healing assay was applied to evaluate the effect of PD-L1 on cell migration in A549, A549-si-PD-L1-RNA, A549/X, and A549/X-si-PD-L1-RNA. Cell migration of individual tumor cells was observed after 6 Gy delivered in three fractions 24 hours later. The wound healing assay clearly demonstrated that radiotherapy plus anti-PD-L1 significantly inhibited cell migration in A549/X cells lines ( Fig. 2A and B) .
The apoptosis rate of A549/X cells was detected by flow cytometry to further explore the correlation between PD-L1 and apoptosis. A significantly higher percentage of apoptotic cells was found in A549 cells after delivery of 6 Gy in three fractions (7.8%) in comparison with those without radiation (1.2%) ( Fig. 2Ca and Cb). In A549-si-PD-L1-RNA cells, radiation also significantly increased the percentage of apoptotic cells (10.1% versus 4.1% [ Fig. 2Cc and Cd). The percentage of apoptotic cells was not significantly altered after delivery of 6Gy in three fractions in A549/X cells (0.5% versus 0.5% [ Fig. 2Ce and Cf), suggesting that A549/X cells were resistant to radiation. The most interesting finding was that when A549/X cells were transfected with si-PD-L1-RNA plus radiation, the percentage of apoptotic cells was significantly increased compared with that in the cells without radiation (59.7% versus 27.0% [ Fig. 2Cg and Ch]), suggesting that downregulating PD-L1 could alleviate radiation resistance by promoting apoptosis. Further data showed that the expression of Bcl-2 was increased in the A549/X cells whereas Bim protein was decreased in the A549/X cells compared with in A549 cells (Fig. 2D ). After transfection with si-PD-L1-RNA in A549/X cells, Bcl-2 and Bim protein inversely altered (see Fig. 2D ). To further explore the molecules by which PD-L1 inhibits apoptosis, caspase-8 and caspase-3 were detected. The results showed that caspase-8 and caspase-3 levels were decreased in A549/X cells (see Fig. 2D ). After downregulation of PD-L1 expression in A549/X cells, caspase-8 and caspase-3 levels were increased (see Fig. 2D ). Taken together, these data indicate that PD-L1 may induce radioresistance by inhibition of apoptosis-related protein, caspase-8, and caspase-3 and that downregulation of PD-L1 could alleviate radioresistance by promoting apoptosis.
Radiotherapy May Up-regulate PD-L1 through the PI3K/AKT and STAT3 Pathways
The role of the PI3K/AKT and STAT3 pathways in regulation of PD-L1 in NSCLC cell lines positive for echinoderm microtubule associated protein like 4 gene (EML4)-anaplastic lymphoma receptor tyrosine kinase gene (ALK) and melanoma cell lines has been characterized 17, 29 ; therefore, we hypothesized that radiation may induce overexpression of PD-L1 through activation of oncogenic drivers. Notably, the expression of PD-L1, p-AKT, p-STAT3, and NF-kB were up-regulated in A549/X cells (Fig. 3A) . Meanwhile, the expression of p-AKT, p-STAT3, and NF-kB did not change after transfected with si-PD-L1-RNA in A549/X cell lines, suggesting that the PI3K/AKT and STAT3 pathways may induce radioresistance by regulating PD-L1 expression. Because EMT plays a critical role in radioresistance, 17, 18 we further investigated the relationship between PD-L1 expression and EMT. The results indicated that the expression of E-cadherin was decreased in the A549/X cell line whereas the levels of expression of vimentin, Snail, and N-cadherin were increased. After transfection with si-PD-L1-RNA, the expression of PD-L1 and the aforementioned EMT-related proteins altered inversely, indicating that PD-L1 may induce radioresistance by promoting EMT (Fig. 3B) . As known of the clear relationship between transforming growth factor-b (TGF-b) and EMT, the expression of TGF-b was further detected in the cell lines A549, A549-si-PD-L1, A549/X, and A549/X-si-PD-L1. As shown in Figure 3C , TGF-b expression was increased in the A549/X cell line whereas TGF-b expression did not change in the cell line A549/X-si-PD-L1.
Through the IP assay, we discovered that TRIM 21 may directly bond with PD-L1. Notably, the expression of TRIM21 was decreased in A549/X cell lines compared with in A549 cell lines and up-regulated when transfected with siRNA-PD-L1 in A549 and A549/X cell lines, suggesting that Trim21 was a downstream protein of PD-L1 and that PD-L1 may induce radioresistance through downregulation of TRIM21 (Fig. 3C and D) .
Synergistic Effect of Radiotherapy and anti-PD-L1 Treatment in a Mouse Model
Given these observations, radiation-induced upregulation of PD-L1 expression was associated with the response to radiotherapy. Therefore, we hypothesized that blockade of PD-L1 may improve response to radiotherapy. To verify this hypothesis, an LLC cancer model was established and treated with anti-PD-L1 antibody alone, radiotherapy alone (6 Gy delivered in three fractions, once a day), and anti-PD-L1 plus radiotherapy. Anti-PD-L1 antibody alone had no significant impact on tumor growth, whereas radiotherapy slowed tumor progression. Notably, radiotherapy in combination with anti-PD-L1 antibody effectively enhanced the inhibition of tumor growth when compared with anti-PD-L1 antibody alone (p < 0.01) and radiotherapy alone (p < 0.01) (Fig. 4A) . 
Radiotherapy in Combination with Anti-PD-L1 Antibody Reduces the Accumulation of MDSCs and iTregs and Increases the Infiltration of CD8-Positive T Cells
MDSCs have been demonstrated to be correlated with radioresistance that can suppress immune responses and facilitate tumor progression. 30 iTregs are key mediators of peripheral tolerance that actively suppress effector T cells. 31 Therefore, we further examined the impact of radiotherapy and anti-PD-L1 combination therapy on MDSCs and iTregs. First, consistent with the aforementioned observations, PD-L1 expression was significantly reduced in the mouse model treated with radiotherapy plus anti-PD-L1 antibody compared with that treated with anti-PD-L1 antibody alone (p ¼ 0.015 [ Fig. 4B] ) whereas PD-L1 expression was increased after radiotherapy (see Fig. 4B ). Afterward, we assessed the expression of CD8-positiveT cells, MDSCs, and iTregs and found that levels CD8-positive T cells were significantly increased (p ¼ 0.038 [ Fig. 4C]) , whereas levels of iTregs (CD4-positive, Fox3p-positive) (p ¼ 0.034 and 0.012 [ Fig. 4D]) and MDSCs (LyGr-positive, CD11b-positive) were significantly reduced (p ¼ 0.018 and 0.036 [ Fig. 4E ]) when treated with radiotherapy and anti-PD-L1 combination therapy in a mouse model. Notably, compared with anti-PD-L1 therapy alone, combination therapy exhibited the greatest effect on MDSCs and iTregs. Taken together, these data indicate that radiotherapy in combination with anti-PD-L1 anbitody synergistically enhanced antitumor immunity by reducing the accumulation of MDSCs and iTregs and promoting CD8-positive T-cell infiltration. Two representative cases that revealed the correlation between the expression of PD-L1, MDSCs, and iTregs and radiotherapy response are presented in Figures 5A and B.
Discussion
Fractionated radiotherapy results in adaptive alterations in the tumor microenvironment that may limit the magnitude and durability of the antitumor immune response. The PD-1/PD-L1 axis plays a pivotal role in host immune surveillance and regulation of the tumor microenvironment; therefore, inhibition of this pathway may release the hounds of immune response and generate durable antitumor responses to radiotherapy. In the present study, we have shown that PD-L1 expression is up-regulated after delivery of conventionally fractionated radiotherapy. Importantly, in models of lung cancer, we have demonstrated that combined radiotherapy and anti-PD-L1 antibody enhance host antitumor immunity and improve the antitumor efficacy over that of either treatment alone by reducing the accumulation of MDSCs and iTregs and stimulating CD8-positive T-cell infiltration. Furthermore, in the 76 patients with NSCLC who received concurrent chemoradiotherapy, our data reveal that the expression of PD-L1 in pretreated tumor tissue is inversely correlated with radiotherapy response, suggesting that PD-L1 expression may be a potentially predictive biomarker for response to radiotherapy in patients with NSCLC.
Although the safety and efficacy of anti-PD-1/PD-L1 antibodies in patients with advanced NSCLC has been demonstrated, most patients cannot derive survival benefits. 22, 23, 32 In addition to identifying predictive biomarker, recent investigations have also focused on combination schemes to broaden clinical utility and efficacy, including in combination with targeted therapy, chemotherapy, and antiangiogenesis therapy. [33] [34] [35] Our results suggest that radiotherapy plus anti-PD-L1 antibody synergistically enhances host antitumor response by elimination of iTregs' and MDSCs' infiltration into the tumor microenvironment. It has been well documented that iTregs are key mediators of immune suppression that actively suppress effector T cells and inhibit immunity disorders in tumors and that MDSCs can negatively regulate T-cell function and facilitate immune escape. 30, 31, [36] [37] [38] [39] [40] Therefore, by elimination of these inhibitory immune cells and stimulation of CD8-positive T-cells' infiltration into the tumor microenvironment, the immunosuppressive environment is reversed through inhibition of the PD-1/PD-L1 pathway. Therefore, our data provide a strong rationale for this combination scheme in NSCLC. Another important issue for the combination therapy is the choice of radiation dosage. As in the previous study by Dovedi et al., 19 we focus on conventionally fractionated radiotherapy (6 Gy delivered in three fractions, once a day) combined with anti-PD-1 antibody in regulating PD-L1 expression and improving immune response. Previous research mainly addressed the synergistic efficacy and "abscopal effect" of high-dose radiotherapy combined with anti-PD-1 therapy. 20, [41] [42] [43] However, because of a lack of direct comparison of conventionally fractionated radiotherapy and high-dose radiotherapy, the optimal radiation dosage in combination with anti-PD-L1 therapy needs further investigation. As most patients receive low-dose radiotherapy in the clinic, our study has important implications for future clinical trial design.
Consistent with previous observations, PD-L1 expression is up-regulated after delivery of fractionated radiotherapy. In colon carcinoma cells, IFN-g produced by CD8-positive T cells is responsible for adaptive upregulation of PD-L1. 19 However, how radiation is involved in modulation of PD-L1 expression is not yet completely understood. Increasing evidence has demonstrated that PD-L1 expression can be mediated by activation of oncogenic signaling pathways in which mitogen-activated protein kinase and the PI3K/AKT pathway play an important role.
14 Studies have also shown that transcriptional factors and epigenetic factors also drive the expression of PD-L1. 29, 44 Our study has also demonstrated that conventionally fractionated radiotherapy may lead to upregulation of PD-L1 expression on tumor cells through activation of the PI3K/AKT and STAT3 pathways. In anaplastic lymphoma kinase-derived pulmonary adenocarcinoma, PD-L1 expression can be up-regulated by activation of STAT3 and hypoxia-inducible factor-1a under normoxia and hypoxia. 45 In addition, activation of the MEK/ERK and PI3K/AKT signaling pathways is also involved in PD-L1 regulation in NSCLC cells harboring either EML4-ALK rearrangement or EGFR activating mutations. 17 These findings reveal a direct link between oncogenic drivers and PD-L1 expression. Moreover, our data may further provide a close interaction between radiation, PD-L1 expression and signaling pathways and suggest that radiation-induced upregulation of PD-L1 expression may also be driven by activation of oncogenic drivers. However, to illustrate the detailed mechanisms of oncogenes that drive the expression of PD-L1 after radiation, further studies are needed.
Prior researchers have demonstrated that PD-L1 is overexpressed in several cancers and correlated with poor prognosis in patients with these malignancies, including NSCLC. 46 Data from KEYNOTE-024 has showed the superiority of pembrolizumab over first-line chemotherapy for advanced NSCLC with a high level of PD-L1 expression (!50% of tumor cells), 47 indicating that PD-L1 expression is a biomarker predictive of response to pembrolizumab. However, the predictive value of PD-L1 expression for the response to radiotherapy in NSCLC has not yet been determined. Our study has for the first time demonstrated that PD-L1 expression is associated with the response to radiotherapy in patients with NSCLC. In our study, patients with negative PD-L1 expression had a significantly higher ORR (88% versus 43.1% [p < 0.001]) and DCR (100% vs 86.2% [p ¼ 0.026]) than those with positive PD-L1 expression, although a lack of mature survival data currently exists. Similarly, in the study by Tokito et al., 48 in 74 patients with stage III NSCLC treated with concurrent chemoradiotherapy, patients with positive PD-L1 expression tended to have poorer overall survival (24.9 months versus 36.9 months). Notably, recent findings also demonstrate that PD-L1 may be a predictor for radiation response in patients with bladder cancer and esophageal squamous cell carcinoma. 49, 50 The role of PD-L1 expression in predicting radiation response deserves further investigation.
In summary, we have demonstrated that conventionally fractionated radiotherapy in combination with anti-PD-L1 antibody can stimulate CD8-positive T-cell infiltration and eradicate the local accumulation of iTregs and MDSCs, which alter the tumor microenvironment and result in a synergistic antitumor immunity in NSCLC. Moreover, PD-L1 expression may predict the response to radiation treatment in patients with NSCLC. Our study provides a rationale for design of a future clinical trial to investigate the efficacy of conventionally fractionated radiotherapy plus anti-PD-1/PD-L1 antibody. In addition, further studies are also warranted to investigate the role of PD-L1 expression in guiding tailored radiotherapy in patients with NSCLC.
